

# E Guttman-Yassky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875618/publications.pdf>

Version: 2024-02-01

55  
papers

2,589  
citations

257450

24  
h-index

206112

48  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2430  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British Journal of Dermatology, 2021, 184, 437-449.	1.5	289
2	Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 2019, 181, 459-473.	1.5	288
3	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. British Journal of Dermatology, 2020, 183, 242-255.	1.5	277
4	Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment. Experimental Dermatology, 2018, 27, 340-357.	2.9	209
5	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology, 2018, 178, 768-775.	1.5	127
6	The oral Janus kinase/spleen tyrosine kinase inhibitor ASP002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. British Journal of Dermatology, 2019, 181, 733-742.	1.5	96
7	Obesity alters pathology and treatment response in inflammatory disease. Nature, 2022, 604, 337-342.	27.8	93
8	Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis. Journal of Experimental Medicine, 2021, 218, .	8.5	68
9	Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. British Journal of Dermatology, 2007, 157, 1103-1115.	1.5	65
10	Nonlesional atopic dermatitis skin shares similar T cell clones with lesional tissues. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 2017-2025.	5.7	62
11	Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 314-325.	5.7	61
12	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 59-70.	5.7	58
13	Phase 2a randomized clinical trial of dupilumab (anti-IL4/IL13) for alopecia areata patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 897-906.	5.7	51
14	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1224-1231.	2.4	50
15	Keloid lesions show increased IL4/IL13 signaling and respond to Th2-targeting dupilumab therapy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e161-e164.	2.4	50
16	Global Allergy Forum and 3rd Davos Declaration 2015. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 588-592.	5.7	47
17	Identification of unique proteomic signatures in allergic and non-allergic skin disease. Clinical and Experimental Allergy, 2017, 47, 1456-1467.	2.9	45
18	Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T cell populations. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 713-723.	5.7	45

#	ARTICLE	IF	CITATIONS
19	Early intervention and prevention of allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 416-441.	5.7	44
20	Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 45-58.	5.7	41
21	Circulating CLA <sup>+</sup> T cells in atopic dermatitis and their possible role as peripheral biomarkers. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 366-372.	5.7	40
22	Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing. <i>British Journal of Dermatology</i> , 2020, 183, 1083-1093.	1.5	40
23	Î”Np63 regulates IL-33 and IL-31 signaling in atopic dermatitis. <i>Cell Death and Differentiation</i> , 2016, 23, 1073-1085.	11.2	38
24	Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nursesâ€™ Health Study 2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 831-834.	5.7	33
25	SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 875-878.	5.7	29
26	EAACI Biologicals Guidelinesâ€”dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 988-1009.	5.7	24
27	Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. <i>F1000Research</i> , 2017, 6, 1712.	1.6	23
28	Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3107-3121.	5.7	23
29	Dust mite induces multiple polar T cell axes in human skin. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1648-1660.	2.9	22
30	Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2510-2523.	5.7	20
31	EAACI Biologicals Guidelinesâ€”Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 17-38.	5.7	19
32	Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. <i>F1000Research</i> , 2017, 6, 1712.	1.6	18
33	Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 1319-1332.	2.0	18
34	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	2.4	15
35	An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3053-3065.	5.7	15
36	Evidence for different immune signatures and sensitization patterns in sub-Saharan African vs. Central European atopic dermatitis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e140-e142.	2.4	14

#	ARTICLE	IF	CITATIONS
37	A plea for standardization of confocal microscopy and optical coherence tomography parameters to evaluate physiological and para-physiological skin conditions in cosmetic science. <i>Experimental Dermatology</i> , 2021, 30, 911-922.	2.9	14
38	The role of circulating eosinophils on COVID-19 mortality varies by race/ethnicity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 925-927.	5.7	14
39	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. <i>Nature Medicine</i> , 2022, 28, 626-629.	30.7	12
40	Chronic hand eczema understanding has ramifications on clinical management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e429-e430.	2.4	11
41	Distinct skin microbiome community structures in congenital ichthyosis. <i>British Journal of Dermatology</i> , 2022, 187, 557-570.	1.5	11
42	Ustekinumab as therapy for psoriasis in a 2-year-old girl. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e109-e110.	2.4	8
43	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020, 10, e039928.	1.9	8
44	The erythema Q-score, an imaging biomarker for redness in skin inflammation. <i>Experimental Dermatology</i> , 2021, 30, 377-383.	2.9	8
45	T <sub>H</sub> 2 cytokines and <i>Staphylococcus aureus</i> cooperatively induce atopic dermatitis-like transcriptomes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3534-3537.	5.7	7
46	Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes. <i>British Journal of Dermatology</i> , 2022, 187, 539-547.	1.5	7
47	High-dimensional analysis defines multicytokine T cell subsets and supports a role for IL21 in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3080-3093.	5.7	6
48	P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i514-i514.	1.3	6
49	544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1). <i>Journal of Investigative Dermatology</i> , 2019, 139, S94.	0.7	5
50	Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa. <i>Nature Communications</i> , 2021, 12, 2557.	12.8	5
51	Atopic dermatitis among children and adolescents in the Arctic region – a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1642-1654.	2.4	5
52	Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. <i>British Journal of Dermatology</i> , 2021, 185, 203-205.	1.5	3
53	Chronic idiopathic urticaria: what is the meaning of skin reactivity to autologous serum? A response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 136-136.	2.4	1
54	Pioneering global best practices in atopic dermatitis: results from the atopic dermatitis quality of care initiative. <i>Clinical and Experimental Dermatology</i> , 2021, , .	1.3	1

#	ARTICLE	IF	CITATIONS
55	Response to "Lack of efficacy of dupilumab in the treatment of keloid disorder"™ by MH Tirgan and J Uitto. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0